抗登革病毒药物研究进展  

Research progress in anti⁃dengue virus drugs

作　　者：王若钰 张超[1] 白洁 徐东刚 WANG Ruoyu;ZHANG Chao;BAI Jie;XU Donggang(Academy of Military Medical Sciences,Academy of Military Sciences,Beijing 100850,China;School of Public Health,Hebei University,Baoding,Hebei 071000,China)

机构地区：[1]军事科学院军事医学研究院,北京100850 [2]河北大学公共卫生学院,河北保定071000

出　　处：《军事医学》2024年第12期931-939,共9页Military Medical Sciences

摘　　要：登革病毒属于黄病毒科正黄病毒属,其感染引起的登革热是一种蚊媒传播的急性传染病,严重时可引发登革出血热和登革休克综合征等,严重危害人类健康。登革病毒对全球公共卫生造成了重大威胁,但目前尚无安全有效治疗登革热的特效药物,其药物研发面临巨大挑战。该文阐释了抗病毒药物研发的重要性和迫切性;总结了近年来各类登革病毒抑制剂的开发情况,分为靶向病毒结构蛋白和非结构蛋白的直接作用于登革病毒的候选药物,和靶向宿主受体的抗病毒候选药物;梳理了基于各类靶点的抑制剂研究进展和作用机制,以期为抗病毒药物研发和登革热治疗提供借鉴。The dengue virus,a member of the Flavivirus genus within the Flaviviridae family,is responsible for dengue fever,an acute mosquito-borne infectious disease that can progress to severe forms such as dengue hemorrhagic fever and dengue shock syndrome,taking a heavy toll on human health.Despite its impact on global public health,there are currently no specific drugs available that are both safe and effective for the treatment of dengue fever so that the research and development of related drugs are facing huge challenges.This paper not only pointed to the critical importance and urgency of developing antiviral medications,but also reviewed recent advancements in the development of dengue virus inhibitors of two categories:candidate drugs that directly target viral structural and non-structural proteins,and antiviral candidate agents that focus on host receptors.Additionally,this paper provided an overview of the progress in and the mechanisms of various inhibitors in the hope of providing a reference for antiviral drug development and the treatment of dengue fever.

关 键 词：登革病毒 登革热 抗病毒药物 病毒蛋白靶标 宿主蛋白靶标 

分 类 号：R914[医药卫生—药物化学]